Neonatal but not juvenile gene therapy reduces seizures and prolongs lifespan in SCN1B–Dravet syndrome mice
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci182584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Chunling Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Epilepsies, Myoclonic, Seizures, Voltage-Gated Sodium Channel beta-1 Subunit. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NINDS, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Dravet syndrome (DS) is a developmental and epileptic encephalopathy (DEE) that begins in the first year of life. While most cases of DS are caused by variants in SCN1A , variants in SCN1B , encoding voltage-gated sodium channel β1 subunits, are also linked to DS or to the more severe early infantile DEE. Both disorders fall under the OMIM term DEE52. Scn1b- null mice model DEE52, with spontaneous generalized seizures and death in 100% of animals in the third postnatal week. Scn1b- null cortical parvalbumin-positive interneurons and pyramidal neurons are hypoexcitable. The goal of this study was to develop a proof-of-principle gene replacement strategy for DEE52. We tested an adeno-associated viral vector encoding β1 subunit cDNA (AAV-Navβ1) in Scn1b- null mice. We demonstrated that AAV-Navβ1 drives β1 protein expression in excitatory and inhibitory neurons in mouse brains. Bilateral intracerebroventricular administration of AAV-Navβ1 in Scn1b- null mice at postnatal day 2 (P2), but not at P10, reduced spontaneous seizure severity and duration, prolonged lifespan, prevented hyperthermia-induced seizures, and restored cortical neuron excitability. AAV-Navβ1 administration to WT mice resulted in β1 overexpression in brain but no obvious adverse effects. This work lays the foundation for future development of a gene therapeutic strategy for patients with SCN1B -linked DEE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Department of Pharmacology and Toxicology and.
- Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.
Förderung
- NINDS NIH HHS
- NINDS
- Canadian Institutes of Health Research
- Canadian Rare Diseases Models and Mechanisms Network
Zitieren
APA
Chen, C., Yuan, Y., O'Malley, H. A., Duba-Kiss, R., Chen, Y., Habig, K., Niibori, Y., Hodges, S. L., Hampson, D. R., & Isom, L. L. (2025). Neonatal but not juvenile gene therapy reduces seizures and prolongs lifespan in SCN1B–Dravet syndrome mice. Journal of Clinical Investigation. https://doi.org/10.1172/jci182584
Vancouver
Chen C, Yuan Y, O'Malley HA, Duba-Kiss R, Chen Y, Habig K, et al. Neonatal but not juvenile gene therapy reduces seizures and prolongs lifespan in SCN1B–Dravet syndrome mice. Journal of Clinical Investigation. 2025. doi:10.1172/jci182584
BibTeX
@article{Chen2025,
author = {Chen, Chunling and Yuan, Yukun and O'Malley, Heather A and Duba-Kiss, Robert and Chen, Yan and Habig, Karl and Niibori, Yosuke and Hodges, Samantha L and Hampson, David R and Isom, Lori L},
title = {Neonatal but not juvenile gene therapy reduces seizures and prolongs lifespan in SCN1B–Dravet syndrome mice},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci182584}
}
EUVIMED